E. Gore

发表

A hit deconstruction approach for the discovery of fetal hemoglobin inducers.

H. Eberl, A. Gilmartin, Zining Wu, 2018, Bioorganic & medicinal chemistry letters.

Functional Cellular Responses and Cytokine Profiles

E. Gore, 2008 .

In vitro and in vivo induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor

J. Luengo, Mark Cockerill, D. Mcnulty, 2020, Haematologica.

Flow Cytometry in the Preclinical Development of Biopharmaceuticals

D. Williams, Donna M. Williams, K. Gossett, 1999, Toxicologic pathology.

Immunomodulatory Effects of Anti-CD4 Antibody in Host Resistance against Infections and Tumors in Human CD4 Transgenic Mice

P. Bugelski, T. Hart, D. Herzyk, 2001, Infection and Immunity.

Immune function tests for hazard identification: a paradigm shift in drug development.

E. Gore, 2006, Basic & clinical pharmacology & toxicology.

Development of Phenotypic Screening Assays for γ-Globin Induction Using Primary Human Bone Marrow Day 7 Erythroid Progenitor Cells

Xin Zeng, Francesca Zappacosta, R. Ames, 2013, Journal of biomolecular screening.

Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.

Rafael Ponce, Lakshmi Amaravadi, Gopi Shankar, 2009, Regulatory toxicology and pharmacology : RTP.

Immunopharmacology of recombinant human interleukin-18 in non-human primates.

P. Bugelski, J. Soos, Z. Jonak, 2002, Cytokine.

Primary antibody response to keyhole limpet hemocyanin in rat as a model for immunotoxicity evaluation.

D. Herzyk, D. Ennulat, Edit Kurali, 2004, Toxicology.

Adequate immunotoxicity testing in drug development.

D. Herzyk, E. Gore, 2004, Toxicology letters.

Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4.

C. Davis, T. Hart, D. Herzyk, 2000, The Journal of pharmacology and experimental therapeutics.